100%. Everything in this announcement is positive, other than the loss of one patient which is recognised that they had the more aggressive type of MND, AND was on the weakest trial doses the whole time. The Ph1 data showed how well the 10 mg/kg cohort responded to MPL, which of course is what PAA are moving forward with in the OLE & the Ph2.
Ann: Appendix 4C & Quarterly Update, page-18
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.005(2.38%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $276.5K | 1.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17811 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 186052 | 5 |
View Market Depth
| Last trade - 15.30pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.005 ( 2.23 %) |
||||
| Open | High | Low | Volume | ||
| 21.5¢ | 22.5¢ | 21.0¢ | 629786 | ||
| Last updated 15.58pm 03/06/2024 ? | |||||
| PAA (ASX) Chart |